What guidance did Verastem's management provide for the next earnings period?

What were the key takeaways from Verastem's earnings call?

What is the market's earnings forecast for Verastem next quarter?

What were the key takeaways from Verastem’s earnings call?

What is Verastem's latest dividend and current dividend yield?

What does Verastem do and what are its main business segments?

Did Verastem beat or miss consensus estimates last quarter?

What is the revenue and EPS growth rate for Verastem year over year?

- **Commercial Success**: $11.2 million Q3 revenue, 133 prescribers, 65% top 100 org engagement.
- **Clinical Momentum**: Expanded RAMP-205, RAMP-301 enrollment; VS-7375 Phase I/IIa safety positive.
- **Financial Health**: $137.7 million cash, $29M R&D, $21M SG&A.
- **Key Risks**: NCCN label expansion uncertain; patient retention data maturing.

**【CEO Summary Section】**
- **Q3 2025 Financial Highlights**: Achieved $11.2 million net product revenue, surpassing expectations, driven by strong adoption of AVMAPKI FAKZYNJA CO-PACK in KRAS-mutated recurrent LGSOC.
- **Commercial Execution**: 133 prescribers engaged, with 65% of prescriptions from top 100 healthcare organizations. Academic and community oncologists contributed equally (50% each), with 60% of scripts from gynecologic oncologists.
- **Clinical Pipeline Progress**: Expanded enrollment in RAMP-205 (first-line pancreatic cancer) and RAMP-301 (recurrent LGSOC). VS-7375 Phase I/IIa trial showed no Grade 2+ GI toxicities at Phase II dose.

**【CFO Financial Commentary】**
- **Revenue and Costs**: $11.2 million net product revenue; cost of sales $1.7 million. R&D expenses $29 million (driven by clinical trials and drug production). SG&A expenses $21 million (commercial launch and operations).
- **Financial Position**: Cash, cash equivalents, and investments totaled $137.7 million, providing runway into H2 2026. Non-GAAP net loss $39.4 million ($0.54 per share).

**【Q&A Key Highlights】**
- **Patient Dynamics**: Early data shows mixed lines of therapy (first recurrence and later lines), with KRAS mutant patients dominant. Refill rates and new starts balanced, but detailed metrics pending.
- **Clinical Trial Updates**: IDMC recommended modest RAMP-301 enrollment increase (30 patients) due to faster accrual and event rates. VS-7375 tolerability superior to Chinese partner's data, with no Grade 2+ GI tox.
- **Strategic Priorities**: Focus on physician engagement, reimbursement efficiency, and expanding AVMAPKI FAKZYNJA CO-PACK adoption. NCCN committee review outcome pending, could expand label to wild-type LGSOC.

Verastem, Inc. (VSTM) Q3 2025 Earnings Call Transcript

- **Breakthrough Launch**: AVMAPKI FAKZYNJA CO-PACK achieved $2.1 million in net revenue within 6 weeks, marking the first FDA-approved therapy for KRAS-mutated recurrent LGSOC.
- **Operational Excellence**: Product availability within 5 days of FDA approval and 93% coverage of top healthcare providers highlight strong execution.
- **Financial Strength**: $164.3 million cash runway supports ongoing commercial efforts and clinical development.
- **Future Growth**: Upcoming Phase III trials and regulatory expansion in Japan and EU position the company for sustained momentum.

**【Management Opening Remarks】**
- Julissa Viana welcomed participants, highlighted the press release and slide presentation, and reminded of forward-looking statements. She introduced the speakers and turned the call over to CEO Dan Paterson.

**【CEO Commentary】**
- Dan Paterson emphasized the transformative Q2 2025, noting FDA approval of AVMAPKI FAKZYNJA CO-PACK for KRAS-mutated recurrent LGSOC and its first commercial launch. The product generated $2.1 million in net revenue within 6 weeks, reflecting strong execution across all launch priorities. He highlighted the company's operational excellence, with the product available at specialty pharmacies within 5 days of approval. He also outlined future milestones, including Phase III trials and potential expansion of the product's indication.

**【Commercial Launch Discussion】**
- **Matt Ros**: Discussed the launch strategy focusing on healthcare provider engagement, patient support, and seamless access. The team achieved 93% coverage of top 100 parent organizations and 84% of top 100 office locations within 6 weeks. Prescriptions were seen across academic and community settings, with positive feedback on the product's safety and efficacy. The combination therapy was well-tolerated, with low discontinuation rates.
- **Mike Crowther**: Provided details on early launch dynamics, including high engagement from priority accounts and spontaneous use outside targeted sites. The team leveraged digital outreach and GPO agreements to broaden reach. Payer coverage was broad, with minimal delays in reimbursement, and the $0 copay program minimized patient financial burden.

**【CFO Financial Commentary】**
- **Dan Calkins**: Reported Q2 2025 financials, including $2.1 million in net product revenue. R&D expenses increased to $24.8 million due to clinical trial costs and production activities, while SG&A decreased to $2.7 million due to commercial readiness efforts. The company ended the quarter with $164.3 million in cash, supported by a $75 million private placement, providing a cash runway into 2026.

**【Q&A Highlights】**
- **Launch Performance**: Management emphasized early traction, with scripts from both targeted and spontaneous prescribers. The launch team's ability to engage hard-to-access accounts was a key driver of success. Gross to net expectations were aligned with industry norms (15-20%).
- **Payer Dynamics**: Reimbursement was seamless, with minimal delays. Medicare patients benefited from the $2,000 out-of-pocket cap, while commercial patients had 0 copay support.
- **Regulatory Pathways**: Japan may see conditional approval based on a bridging study, while EU efforts are pending scientific guidance. The company prioritizes making the product available in Europe despite potential reimbursement challenges.
- **Clinical Pipeline**: Encouraging data from the VS-7375 trial in China and plans for U.S. Phase I updates. The RAMP 301 trial aims to expand the product's indication to all LGSOC patients, regardless of KRAS mutation status.

VSTM

VSTM fundamentals

Earnings Call

You can ask Aime